Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A **combination pharmaceutical** consisting of three active ingredients: **orphenadrine citrate**, **aspirin**, and **caffeine**. Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic and possible analgesic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) providing analgesic, antipyretic, and anti-inflammatory effects primarily via inhibition of cyclooxygenase; caffeine is a central nervous system stimulant that may enhance analgesic effects by antagonizing adenosine receptors. This drug combination is indicated for the symptomatic relief of mild to moderate pain associated with acute musculoskeletal disorders, used as an adjunct to rest and physical therapy[1][2][3][7][9][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on orphenadrine citrate + aspirin + caffeine.